Shilpa Medicare's Subsidiary Receives EDQM Certification for Teriflunomide API

Shilpa Pharma Lifesciences Limited, a wholly-owned subsidiary of Shilpa Medicare Limited, has been granted a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines & Healthcare (EDQM) for its Active Pharmaceutical Ingredient (API), Teriflunomide. This certification confirms that Teriflunomide meets the quality standards of the European Pharmacopoeia, facilitating its commercial distribution across European markets. Teriflunomide is primarily used in the treatment of multiple sclerosis, and this approval underscores Shilpa Pharma Lifesciences' commitment to adhering to stringent international quality standards in pharmaceutical manufacturing.

Source: Shilpa Medicare Limited